Atea Pharmaceuticals Inc. (NASDAQ:AVIR) has seen 1.08 million shares traded in the last trading session. The company, currently valued at $2.40B, closed the last trade at $28.91 per share which meant it lost -$0.09 on the day or -0.31% during that session. The AVIR stock price is -225.74% off its 52-week high price of $94.17 and 35.25% above the 52-week low of $18.72. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.19 million shares traded. The 3-month trading volume is 1.37 million shares.
The consensus among analysts is that Atea Pharmaceuticals Inc. (AVIR) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR) trade information
Sporting -0.31% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the AVIR stock price touched $28.91 or saw a rise of 8.69%. Year-to-date, Atea Pharmaceuticals Inc. shares have moved -30.80%, while the 5-day performance has seen it change -7.78%. Over the past 30 days, the shares of Atea Pharmaceuticals Inc. (NASDAQ:AVIR) have changed 3.62%. Short interest in the company has seen 4.25 million shares shorted with days to cover at 11.26.
Wall Street analysts have a consensus price target for the stock at $46.50, which means that the shares’ value could jump 37.83% from current levels. The projected low price target is $37.00 while the price target rests at a high of $56.00. In that case, then, we find that the current price level is -93.7% off the targeted high while a plunge would see the stock gain -27.98% from current levels.
Atea Pharmaceuticals Inc. (AVIR) estimates and forecasts
Figures show that Atea Pharmaceuticals Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -50.84% over the past 6 months, with this year growth rate of 264.71%, compared to 7.50% for the industry. Revenue growth from the last financial year stood is estimated to be 533.70%.
2 analysts offering their estimates for the company have set an average revenue estimate of $60.39 million for the current quarter. 2 have an estimated revenue figure of $55.2 million for the next quarter concluding in Sep 2021.
Atea Pharmaceuticals Inc. is expected to release its next earnings report on March 30 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s Major holders
Insiders own 18.48% of the company shares, while shares held by institutions stand at 58.09% with a share float percentage of 71.26%. Investors are also buoyed by the number of investors in a company, with Atea Pharmaceuticals Inc. having a total of 99 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 6.45 million shares worth more than $269.38 million. As of Dec 30, 2020, FMR, LLC held 7.79% of shares outstanding.
The other major institutional holder is Cormorant Asset Management, LP, with the holding of over 6.41 million shares as of Dec 30, 2020. The firm’s total holdings are worth over $267.87 million and represent 7.75% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Fidelity Series Growth Company Fund. As of Feb 27, 2021, the former fund manager holds about 3.64% shares in the company for having 3.01 million shares of worth $226.82 million while later fund manager owns 0.66 million shares of worth $49.75 million as of Feb 27, 2021, which makes it owner of about 0.80% of company’s outstanding stock.